Comment Comment by mpnagle Hi hi.You may be interested in the VITALITY study out of China from 2022. 400+ people given FOLFOX + Avastin (standard of care, first line for colorectal cancer) vs FOLFOX + Avastin + high dose Vit C.https://pubmed.ncbi.nlm.nih.gov/35929990/Roughly showed no change for the overall population, but a significant increase in progression free survival for folks with RAS mutations.As someone with a stage 4 colorectal cancer with a RAS mutation, this is interesting to me! parent mpnagle 1 year ago
You may be interested in the VITALITY study out of China from 2022. 400+ people given FOLFOX + Avastin (standard of care, first line for colorectal cancer) vs FOLFOX + Avastin + high dose Vit C.
https://pubmed.ncbi.nlm.nih.gov/35929990/
Roughly showed no change for the overall population, but a significant increase in progression free survival for folks with RAS mutations.
As someone with a stage 4 colorectal cancer with a RAS mutation, this is interesting to me!